𝔖 Scriptorium
✦   LIBER   ✦

πŸ“

Valuation in Life Sciences: A Practical Guide

✍ Scribed by Dr. Boris Bogdan, Ralph Villiger (auth.)


Publisher
Springer Berlin Heidelberg
Year
2008
Tongue
English
Leaves
341
Category
Library

⬇  Acquire This Volume

No coin nor oath required. For personal study only.

✦ Synopsis


This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including discounted cash-flow and real options, the authors demonstrate how to value projects, patents, licences, firms and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results.

From the reviews:

Ralph Villiger and Boris Bogdan have written what is sure to become the industry standard reference for valuation of pharmaceutical and biotechnology projects and companies.

Dr. Martin Buckland, Chief Business Officer, Astex Therapeutics, Cambridge, UK

✦ Table of Contents


Front Matter....Pages i-xi
Introduction....Pages 1-9
Fundamentals in Life Sciences....Pages 11-26
Basics of Valuation....Pages 27-81
Valuation in Life Sciences....Pages 83-284
Exercises....Pages 285-309
Case Studies....Pages 311-325
Back Matter....Pages 327-334

✦ Subjects


Finance /Banking; Computer Appl. in Life Sciences; Health Informatics; Pharmacy; Biotechnology; Management/Business for Professionals


πŸ“œ SIMILAR VOLUMES


Valuation in Life Sciences: A Practical
✍ Bogdan B., Villiger R. πŸ“‚ Library πŸ“… 2007 🌐 English

This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable indu

Valuation in Life Sciences: A Practical
✍ Boris Bogdan, Ralph Villiger πŸ“‚ Library πŸ“… 2008 πŸ› Springer 🌐 English

<P>This book is the first complete guide to valuation in life sciences for industryΒ  professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable

Valuation in Life Sciences: A Practical
✍ Boris Bogdan, Ralph Villiger (auth.) πŸ“‚ Library πŸ“… 2010 πŸ› Springer-Verlag Berlin Heidelberg 🌐 English

<p><P>This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuabl

Valuation in Life Sciences: A Practical
✍ Boris Bogdan, Ralph Villiger πŸ“‚ Library πŸ“… 2007 πŸ› Springer 🌐 English

This book is the first complete guide to valuation in life sciences for industryΒ  professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable ind

Valuation in Life Sciences: A Practical
✍ Dr. Boris Bogdan, Ralph Villiger (auth.) πŸ“‚ Library πŸ“… 2007 πŸ› Springer Berlin Heidelberg 🌐 English

<P>This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable i

Valuation in Life Sciences: A Practical
✍ Boris Bogdan, Ralph Villiger πŸ“‚ Library πŸ“… 2010 πŸ› Springer 🌐 English

<span>Valuation is a hot topic among life sciences professionals. There is no clear understanding on how to use the different valuation approaches and how to determine input parameters. Some do not value at all, arguing that it is not possible to get realistic and objective numbers out of it. Some c